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Abstract
Background: Iodine deficiency can adversely affect child development including stunted growth. However, the
effect of iodine supplementation or fortification on prenatal and postnatal growth in children (<18 years) is unclear.
We identified the potential need for a systematic review to contribute to the evidence base in this area. To avoid
duplication and inform the need for a new systematic review and its protocol, we undertook a rapid scoping
review of existing systematic reviews investigating the effect of iodised salt and iodine supplements on growth and
other iodine-related outcomes.
Methods: We searched TRIP and Epistemokinos (latest search date 15 December 2014). All English language
systematic reviews reporting on the effect of iodine supplementation or fortification in any form, dose or regimen
on any iodine-related health outcomes (including but not limited to growth) were included. Eligible systematic
reviews could include experimental or observational studies in pregnant or lactating women or children to age 18.
We tabulated the extracted data to capture the scope of questions addressed, including: author, publication year,
most recent search date, participants, pre-specified treatment/exposure and comparator, pre-specified outcomes,
outcomes relevant to our question and number and type of studies included. Methodological quality of included
reviews was assessed using AMSTAR.
Results: Nine hundred and seventy-six records were screened and 10 reviews included. Most studies were of moderate
methodological quality. Outcomes included assessments of thyroid function, iodine deficiency disorders, mental
development and growth. Populations studied included pregnant women, preterm infants and children into adulthood.
Most reviews looked at direct iodine supplementation or fortification, though some reviews considered iodine status,
including the relationship between iodine intake and iodine biomarkers. Although five reviews pre-specified inclusion of
growth outcomes, none provided synthesised evidence on the effects of iodine supplementation or fortification on
prenatal and postnatal somatic growth.
Conclusions: Our rapid scoping review demonstrates a gap in the evidence base with no existing, up-to-date systematic
reviews on the effects of all forms of iodine supplementation/fortification in all of the relevant population groups on
relevant growth and growth-related outcomes. A new systematic review examining this question will assist in addressing
this gap.
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Introduction
Iodine deficiency has been identified as one of the key
preventable factors that can adversely affect child devel-
opment [1], and is one of the most widespread micronu-
trient deficiencies worldwide [2]. It can result in a
number of developmental and functional abnormalities,
the spectrum of which is referred to as the Iodine Defi-
ciency Disorders (IDD) [3, 4].
As an essential micronutrient and component of the
thyroid hormones, which regulate growth and develop-
ment from conception to adulthood, iodine plays a major
role in normal physical growth and development until well
after birth [5]. The synthesis of the thyroid hormones is
impaired when dietary iodine requirements are not met.
In the first trimester of pregnancy, thyroid hormone from
the mother crosses the placenta to fulfil the needs of the
foetus [6]. It is well established that a deficiency in iodine
during the entire pregnancy may cause thyroid dysfunc-
tion and have irreversible adverse effects on child develop-
ment if moderate or severe [7–9]. Indeed, during the
entire growth period thyroid hormone promotes the
growth and development of peripheral tissues and the
skeleton [5]. Hypothyroidism induced by iodine deficiency
can thus have a negative impact on growth and develop-
ment at all stages of the human growth cycle [7], and can
lead to stunted growth if not addressed [10, 11].
In 2012, the World Health Organization (WHO) spe-
cified six targets for the 2025 Global Nutrition Agenda
[12, 13]. The first was to address stunting. The specific
target: a 40 % reduction in the prevalence of stunting in
children under 5 years by 2025. Addressing stunting has
thus become an urgent priority, and there is increased
interest and need to find effective nutrition interventions
to target this global burden. Stunting in childhood is as-
sociated with both short and long-term consequences,
such as decreased cognitive function, slowed motor and
language development, a decreased performance at
school and a lowered learning capacity [14–17]. Though
the prevalence of stunting is decreasing [18], recent glo-
bal estimates from the United Nations Children’s Fund
(UNICEF), WHO and the World Bank stated that in
2013, 161 million children under 5 years were still
stunted [19]. Despite a continued decline, if current
trends continue the WHO predict that in 2025, 127 mil-
lion children under 5 years around the world will remain
affected by stunted growth [13].
Within the design of health promotion packages for
children, it is commonly overlooked that iodine deficiency
has adverse effects on growth and correction of iodine de-
ficiency is frequently not considered an important con-
tributor in promoting optimal child growth and
potentially reducing the risk of stunting. The most effect-
ive means to assure adequate population iodine nutrition
and prevent IDD is universal salt iodization [4, 20, 21].
Where the coverage of iodised salt is incomplete, daily
iodine supplementation is recommended to pregnant and
lactating women and infants [4]. Doses of iodised oil given
once or at repeated intervals may also be an effective
intervention for vulnerable groups until an effective
iodised salt programme can be implemented [4]. Iodine
can also be provided via regular consumption of micronu-
trient powders, such as those distributed by UNICEF and
World Food Program (WFP) programmes [22] and
through fortification of other foods such as bread, which
has been previously shown to have an impact on the iod-
ine status of school-age children [23, 24].
Despite the clear evidence supporting universal salt
iodisation for the prevention of IDD, there is a lack of
clarity on the effects of iodine-related interventions on
somatic growth and risk of stunting. This information is
key in light of the recent spotlight on finding solutions
for the global stunting burden. To address this gap, we
formulated the following research question: “What are
the effects of iodised salt, iodised oil or iodine supple-
ments compared to placebo or no iodine intervention
on prenatal and postnatal somatic growth of the foetus,
infant and child?” We identified the potential need for a
systematic review to tackle this question.
Synthesis and evaluation of all available relevant re-
search would inform and strengthen the evidence base
in this area. The current best evidence should inform
decisions on health interventions and guidelines, par-
ticularly in resource-poor settings. Systematic reviews
of the effectiveness of interventions, using explicit
methods to reduce bias, have the potential to inform
decision-makers as to which interventions to imple-
ment, modify or withdraw from health care [25]. While
systematic reviews should be used to inform interven-
tions and guidelines, it is not always necessary to do
new reviews. If up-to-date, relevant and high quality
systematic reviews exist, these should be used. Updat-
ing existing reviews, if necessary, is more time and
cost-effective than conducting new reviews. Conse-
quently, before embarking on a new systematic review
and to avoid duplication, we undertook a rapid scoping
review to assess the available synthesised research in
this area.
Objectives
The objectives of this rapid scoping review were to:
 Identify the number of existing systematic reviews
on iodine for prenatal and postnatal growth;
 Assess the nature and scope of existing systematic
reviews on iodine for prenatal and postnatal growth;
 Assess the methodological quality of existing
systematic reviews on iodine for prenatal and
postnatal growth;
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 To identify any gaps in the evidence base for the
effects of iodine for prenatal and postnatal growth
and hence determine whether a new systematic
review in this area is justified.
Review
Search strategy and selection criteria
To identify eligible systematic reviews we searched
TRIP (http://www.tripdatabase.com) and Epistemonikos
(http://www.epistemonikos.org). TRIP is a consistently
updated clinical search engine with emphasis on evi-
dence based medicine and clinical guidelines, including
content from the Cochrane Database of Systematic Re-
views (CDSR) and Pubmed. Epistemonikos is a collab-
orative, multilingual database of research evidence
aiming to provide rapid access to systematic reviews in
health that is maintained by systematically searching 25
databases for systematic reviews, broad synthesis or
structured summaries, including CDSR, Pubmed and
EMBASE.
Comprehensive electronic searches of TRIP and Epis-
temonikos were undertaken on 25th March 2014 and
updated on 15th December 2014. In both instances, we
used a simple, broad search string, being “iod*” and
“systematic review” for TRIP and “iod*” for Epistemoni-
kos. We searched for English language reviews, report-
ing on any iodine treatment or exposure that included
experimental or observational studies in humans. All
non-English and animal studies were excluded. Partici-
pants included were pregnant or lactating women or
children up to the age of 18 years; adult populations
were excluded. We selected studies that investigated
exposure to iodised salt, iodised oil or iodine supple-
mentation in any form, dose or regimen (including
foods and iodine given in conjunction with other
micronutrients) and included any adverse health out-
comes due to iodine deficiency, including, but not lim-
ited to, effects on growth. No specific outcomes (e.g.,
cognitive development, weight-for-height z-scores)
were pre-defined.
Data collection and extraction
Selection of systematic reviews
Two authors (JF and LN) independently screened the
titles and abstracts of all search results and identified
potentially eligible systematic reviews using the pre-
specified eligibility criteria. Where at least one author
considered a study to be relevant, the full text document
of the article was obtained. The first author in consult-
ation with CN and LN did the screening of full text arti-
cles for final inclusion, and any uncertainties were
resolved by discussion among authors. Reasons for ex-
cluding full-text articles were captured.
Data analysis
Relevant information from the eligible systematic re-
views was extracted and tabulated to capture the scope
of the questions that were addressed by each review, in-
cluding: author, year of publication, date of most recent
search, types of participants, pre-specified treatment/ex-
posure and comparator, health outcomes reported rele-
vant to iodine deficiency and the number and types of
studies included in the review. The validated and reliable
AMSTAR tool [26, 27] was applied to each eligible sys-
tematic review to assess the methodological quality of
the review. The maximum AMSTAR score is 11 for sys-
tematic reviews with meta-analyses, and 10 for system-
atic reviews without meta-analyses. Scores of 0 to 4
indicate low methodological quality, 5 to 8 moderate
methodological quality, and 9 to 11 high methodological
quality [28].
Results
The search results and selection process are detailed in
Fig. 1. A broad search string was used in an attempt to
ensure potentially eligible systematic reviews were not
missed. Overall, the two searches yielded 976 records.
After screening the titles and abstracts of all the records
and removing the duplicates, we excluded 965 search
results, as they were ineligible according to the pre-
defined criteria. The majority of excluded studies cov-
ered irrelevant topics such as medical management of
hyperthyroidism; nuclear medicine and radioiodine; skin
antisepsis and wound care; use of iodine in dentistry;
cardiovascular and diabetes care and cancer therapy.
Other reasons for exclusion were incorrect participants
(adults), non-English language publications and incor-
rect study design (not systematic reviews).
The full-text articles of eleven potentially eligible sys-
tematic reviews were obtained. One full text was ex-
cluded [29] as it is a duplicate of an included Cochrane
Review [21]. Three of the ten eligible systematic reviews
were Cochrane Reviews [21, 30, 31]. Seven of the eligible
reviews used narrative synthesis and three included
meta-analyses [8, 32, 33]. The detailed characteristics of
the eligible systematic reviews and the gaps relevant to
our research question identified in the existing reviews
are described in Table 1.
Scope of included studies
Interventions
Eight of the ten systematic reviews look at some form of
iodine intake, specifying either supplementation in vari-
ous forms (salt, iodised oil, iodine supplements, food for-
tified with iodine e.g., bread) [9, 29–32], or exposure to
iodine (i.e., indication of iodine status or thyroid func-
tion) [8, 33, 34]. Two systematic reviews consider mul-
tiple micronutrients: as food fortification [35], or
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micronutrient interventions by supplementation or forti-
fication [36].
Of the five reviews specifying supplementation of iod-
ine intake, one systematic review looks at all forms of
population-based iodine supplementation, e.g., iodised
salt, iodised oil (orally or by injection), iodised water,
iodine tablets, food fortified with iodine (but excluding
multiple micronutrients or food fortification), in com-
parison to placebo, non-iodised control or each other
[30]. Another review focused on any prospective study
investigating the prevention of iodine deficiency disor-
ders using iodised salt, which had a control group (pla-
cebo or other forms of iodine supplementation e.g.,
iodised oil, iodised water) [21]. Three further systematic
reviews investigate direct iodine supplementation (any
form of supplementation [9, 32]; and supplementation
appropriate to premature infants, to achieve an intake of
more than 30 μg per kilogram bodyweight per day [31]).
Setting
Three systematic reviews specify particular settings
with respect to iodine intake: one review focuses expli-
citly on mild to moderate iodine deficiency settings
[32], and two reviews stipulate settings of low iodine in-
take [21, 30]. A further systematic review is focused on
developing countries only [36], however, the remaining
six papers did not specify iodine deficient, replete or
excess settings. Of these six systematic reviews, one
systematic review aims to estimate the dose–response
relationship between iodine intake and iodine status,
but does not address health-related outcomes [33]. It
includes studies from severe, moderate and mild
iodine-deficient settings, and replete settings. Studies
investigating excessive iodine intake were also eligible,
however, no such studies were found.
Study design
Most of the reviews include randomised controlled tri-
als (RCT) as well as other study designs such as non-
randomised trials, quasi-RCTs, prospective compara-
tive studies and cohort studies. Two reviews include
RCTs only [9, 36]. In the majority of the narratively
synthesised reviews, the included studies had control
groups and authors attempt to present a comparative
narrative appraisal when a meta-analysis was not done
or not possible. Three reviews feature meta-analyses
[8, 32, 33]. Conversely, Gunnarsdottir and Dahl [34]
examine the literature available at time of writing, with
the objective of reviewing and updating the fourth
(2004) edition of the Nordic Nutrition Recommenda-
tions. As such, this is different to the other included
reviews in that it does not have specific inclusion cri-
teria for study type or population nor control group,
requiring only that studies are representative of the
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Fig. 1 Flowchart of screening process for eligible reviews
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Table 1 Characteristics of included studies
Author &
year
Aim of study Participants; Study
designs considered
Treatment /
Exposure; Setting
Control, if
applicable
Pre-defined outcomes No. studies; Study
designs included;
Locations
Gaps relevant to our
research question
AMSTAR
score
Last search
date
Quantitative studies (including meta-analyses)
1 Taylor et al.
(2014)
To evaluate the
impact of iodine
supplementation
in pregnancy and
childhood on
thyroid function
and child
School-age children
from populations of
mild-to-moderate iodine
deficiency (determined
from the median popu-
lation urinary iodine)
Maternal iodine
supplementation in
pregnancy;
Childhood iodine
supplementation
No
supplementation
or significantly
lower dose of
supplements
Thyroid function; thyroid
volume; cognitive
performance
17 studies included in
the review, of which 9
RCTs and 8 observational
studies
Review only
covers maternal
and infant thyroid
function, and child
neurodevelopment.
8
Last search
date – April
2013 Ref.:
[32] Setting: Mild to
moderate iodine
deficiency
Relevant studies: 4 RCTs
reporting on neonatal
thyroid function
There are no growth
outcomes
considered.Neurodevelopment in
populations with mild-to
moderate Iodine
deficiency.
RCTs, quasi-randomised
trials, prospective cohort
or case–control studies
considered
Locations: Belgium,
Denmark, Germany and
Spain
Not all relevant age
groups are included
(only neonates and
school age children)
2 Bougma
et al. (2013)
To examine whether
iodine status of mothers
or infants affects the
mental development of
young children
Children 5 years and
under RCT, non-
randomised trial, pro-
spective cohort trials
considered
Exposure to different
iodine levels before
pregnancy, during
pregnancy, or shortly
after birth; or
Examination of
iodine exposure
related to mental
development
outcome
Placebo,
historical control,
iodine sufficient
siblings or
children of
similar age used
as control group
Mental development
score
24 studies included in
the review, of which 2
RCT, 8 non-randomized
intervention trials, 10
prospective cohort
(women), and 9 pro-
spective cohort (infants)
Review only
investigates mental
development.
8
Last search
date –
November
2011 Ref.:
[8]
There are no growth
outcomes
considered.
Not all relevant age
groups are included
(only under 5 years).
Relevant studies: None.
No studies report on
growth (total of 24
studies included in
review)
Setting: Not defined
Locations: China, DR
Congo, Ecuador, Peru,
Spain, Portugal, USA,
Netherlands, Italy, UK,
Canada.
3 Ristić-
Medić et al.
(2014)
To identify and examine
studies investigating
iodine intake and
biomarkers of iodine
status and to combine
these studies in a meta-
analysis to estimate the
dose–response relation-
ships between iodine in-
take and iodine status.
No criteria specified For RCTs: Iodine
intervention (iodised
salt, iodised oil,
iodised water, iodine
tablets, iodine-
enriched food or
milk formula)
For RCTs: Placebo
or low-dose iod-
ine supplement
(<100μg iodine
per day)
For RCTs: Mean
concentrations of UI,
serum Tg, serum TSH,
analytical methods to
assess iodine status
58 studies included in
the review, of which 33
RCTs 30 observational
studies (5 being part of
the included RCTs)
Review looked at
iodine biomarkers.
Does not consider
iodine-related out-
comes i.e., growth.
8
RCTs, prospective cohort
studies, nested case–
control studies, cross
sectional studies
considered
Last search
date –
December
2011 Ref.:
[33]
For observational
studies: Concentration of
UI, serum Tg, serum TSH,
analytical methods to
assess iodine status
Relevant studies: None
Observational
studies: Evaluation of
iodine intake (food
frequency
questionnaire, dietary
Locations: Africa,
Americas, Asia,
Australasia, Europe
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Table 1 Characteristics of included studies (Continued)
history method, 24h
recall, adherence to
WHO criteria for
assessing iodine
intake)
Setting: Not defined
Qualitative studies (not including meta-analyses)
1 Khor &
Misra
(2012) Last
searched
Ref.: [36]
To provide an update on
the effects of
micronutrient
interventions (by
supplementation or food
fortification) on cognitive
performance of children
of 5-15 years in develop-
ing countries
Children 5-15 years RCTs
only considered
Micronutrient
(vitamins and/or
minerals)
supplementation for
a period of >4
months
Not specified Cognitive development
indicators including:
psychomotor
development, cognitive
performance, mental
development, IQ, school
performance.
13 RCTs included in the
review, of which 6 that
considered
micronutrient-fortified
foods including iodine.
Did not consider
growth outcomes.
Not all relevant age
groups are included;
5 – 15 years only.
4
Developing countries
(UN classification)
(Studies that used
other dietary
components such as
essential fatty acids,
functional foods
were excluded.)
Relevant studies: none Only included RCTs.
Locations: Asia, Kenya,
Morocco
Setting: Developing
countries
Only UN-classification
developing countries
included
2 Best et al.
(2011) Last
search date
– not
specified
Ref.: [35]
To examine the impact
of multi-micronutrient
(MMN) food fortification
on the micronutrient sta-
tus, growth, health, and
cognitive development
of school-age children.
School age children.
(defined by 75 % of
study population being
between 6 and 18 years)
MMN-fortified food
(defined as food to
which > 3
micronutrients were
added)
Unfortified food
or food fortified
with only one or
two
micronutrients
Biochemical
measurements of
micronutrient status,
prevalence of
micronutrient
deficiencies, indicators of
growth or body
composition, stunting,
wasting, underweight,
morbidities, absence
from school, cognitive
outcomes, academic
performance.
12 studies included, of
which: 6 controlled
clinical trials (CCT), 1
controlled before-after
(CBA) trial, and 5 RCTs
Looks at multiple MN
rather than just
supplementation
with iodine alone.
6
Experimental controlled
efficacy or effectiveness
studies including quasi-
experimental controlled
clinical trials, and con-
trolled before-after stud-
ies only considered
Setting: Not defined Relevant studies: 1 CCT
compared effects of
MMN fortification to
single fortification with
iodine (Morocco);4
studies reported on
growth outcomes
(height/stunting and
weight/BMI/
underweight)
Fortified food only,
and not
supplementation.
Restricted to English
language
publications.
School age children
only; review does
not consider all
relevant population
groups.
Locations: Asia,
Australasia, India, North
Africa, Southern Africa
3 Gunnars-
dottir &
Dahl (2012)
To assess the influence
of different intakes of
iodine at different life
Not specified, except
that publications must
be either in English or a
Not specified Not specified Pregnancy outcome,
childhood development
(including cognitive
40 studies of mixed
design included, of
which 2 studies (1
Included adults and
elderly as well as
7
Setting: Not defined
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Table 1 Characteristics of included studies (Continued)
Last search
date –
September
2010 Ref.:
[34]
stages (infants, children,
adolescents, adults,
elderly, and during
pregnancy and
lactation), in order to
estimate the
requirement for
adequate growth,
development, and
maintenance of health.
Nordic language; have
>50 subjects; consider
representative samples
of the population or
specific sub-samples of
the population; have an
indicator of iodine status
and/or thyroid function,
e.g.,: UIC, thyroid volume,
TSH, T3 and T4
function and growth),
thyroid function (thyroid
hormones, thyroid gland
size, hyper- and
hypothyroidism),
metabolism, health, and
weight
clinical trial, 1 cohort)
reported on iodine
status in pregnancy,
pregnancy outcome and
thyroid function of
mother and infant 1
cross-sectional study re-
ported on excess iodine
intake and UIC
children and
pregnant women.
Some papers were
excluded on the
basis that they were
not relevant to
Nordic countries.
Does not only cover
intervention studies-
also included are
observational studies.
Locations: Europe,
Nordic countries,
Americas, Eastern
Mediterranean, Africa,
Western Pacific
No specified
intervention or
control.
All study types
considered
4 Zhou et al.
(2013) Last
search date
–
December
2012 Ref.:
[9]
To evaluate the efficacy
and safety of iodine
supplementation during
pregnancy or the
periconceptual period
on the development
and growth of children.
Pregnant or women of
childbearing age,
regardless of iodine
status or gestation at
trial entry
Any form of iodine
supplementation,
with or without
other nutrients.
Absence of
iodine between
exposure groups.
Primary outcome:
cognitive development
of children
8 RCTs included in the
review, of which 2 quasi-
randomised
Only included RCTs. 8
Not all relevant age
groups are included
– children of
pregnant women are
followed after
pregnancy. Does not
consider iodine
supplementation in
children themselves.
RCTs (including quasi-
random design) only
considered
Setting: Not defined Secondary outcomes:
pregnancy and birth
outcomes, childhood
growth and mortality,
iodine status, thyroid
function of mothers and
infants.
Relevant studies: 2 quasi-
RCT, reporting on
growth outcomes (chil-
dren at 5 years follow-up
following intervention:
skinfold thickness, MUAC,
postnatal bone matur-
ation growth rate; height
of children at 15 years
follow up; and preg-
nancy outcomes includ-
ing birth
anthropometrics and
APGAR score)
Locations: Peru, Papua
New Guinea (Q-RCTs);
Belgium, Germany,
Denmark, Italy, Chile.
5 Ibrahim et
al. (2006)
Last search
date –
November
2005 Ref.:
[31]
To determine whether
dietary supplementation
with iodine affects
mortality and morbidity
in preterm infants.
Preterm infants (less
than 37 weeks
completed gestation)
Iodine
supplementation (>
30 μg/kg/day)
Placebo or no
supplementation
Primary outcomes:
Neonatal mortality and
mortality prior to
hospital discharge;
neuro-developmental
outcomes at≥ 12-
months; severe neurode-
velopmental disability;
cognitive and
1 study included, which
was an RCT.
Only preterm infants
considered.
9
Relevance of study:
Primary outcome was
thyroid hormones
Does not include
pregnancy, nor older
infants or children.
Controlled trials using
random or quasi-random
patient allocation
considered
Setting: Not defined
Location: UK Not focussed on
growth, rather the
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Table 1 Characteristics of included studies (Continued)
educational outcomes at
age > 5 years
prevention of
mortality and
adverse
neurodevelopmental
outcomes following
preterm births.
Secondary outcomes:
Severe respiratory
distress syndrome;
biochemical measures of
thyroid function and
iodine status
6 Angermeyr
& Clar
(2004) Last
search date
- October
2003 Ref.:
[30]
To assess the effects of
iodine supplementation
(e.g., iodised oil, salt,
water, bread,
supplements, tablets) in
comparison with
placebo or with each
other on outcomes
relating to iodine
deficiency disorders in
children
Children ≤ 18 years living
in areas with low iodine
intake (iodine deficiency)
Any population-
based iodine supple-
mentation (e.g.,
iodised salt, iodised
oil (given orally or by
injection), iodised
water, iodine tablets
iodine added to food
etc.)
Placebo or other
iodine
supplementation
Primary outcomes:
Goitre rate and thyroid
size
Total 26 studies
included, of which 15
RCTs, 5 non-randomised
controlled trials, 3 pro-
spective controlled stud-
ies, 2 quasi-randomised
trials, 1 prospective com-
parative study.
Review does not
cover pregnancy.
9
Physical development
(height, weight,
strength); mental
development
(measurement of
cognitive function) Relevant studies:22
studies measured one or
more thyroid outcomes
(goitre rate, thyroid size,
urinary iodine excretion,
THS, T3, T4,
thyroglobulin).
Setting: Low iodine
intake
Secondary outcomes:
Mortality related to
iodine deficiency
disorders; symptoms and
signs of hypothyroidism;
urinary iodine
concentration; blood
TSH concentration;
serum thyroglobulin
concentration; adverse
effects (e.g., iodine-
induced hyperthyroid-
ism, thyroid auto-
antibodies); health-
related quality of life; ac-
ceptability of supple-
ment; compliance, costs;
socioeconomic effects
(e.g., school
performance)
6 studies measured one
or more growth
outcome measures
(height, weight,
mortality)
Locations: North Africa,
Asia Europe, India, Africa,
Americas
RCT, quasi-randomised
trials and prospective
non-randomised experi-
mental studies
considered
7 Wu et al.
(2002)
(updated
2004) Last
search date
– August
2004 Ref.:
[21]
To assess the effects of
iodised salt in
comparison with
placebo and other forms
of iodine
supplementation on the
incidence of iodine
deficiency disorders
Adults and children
living in areas of low
iodine intake
Iodised salt Placebo, other
forms of iodine
supplementation
(iodised oil,
iodised water,
etc.)
Primary outcomes:
Mortality related to
iodine deficiency
disorders, goitre, physical
and mental
development in
children, symptoms of
hypothyroidism.
6 studies included, of
which 1 RCT, 3 RCT (not
blinded, blinding
unknown, participants
unblinded outcome
assessment blinded), 2
prospective controlled
study
Only covers iodised
salt.
9
Setting: Low iodine
intake
Any prospective study
with a control group
considered
All study types (with
control group)
considered
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Table 1 Characteristics of included studies (Continued)
Secondary outcomes:
UIC, TSH in blood and
neonatal cord blood,
serum thyroglobulin,
adverse effects (e.g.,
iodine induced
hyperthyroidism), health
related quality of life,
costs, compliance,
socioeconomic effects
Also considers adultsRelevant studies: 1 RCT
reported on UIC
Locations: Germany,
China, South Africa, Italy,
Malaysia, India
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Nordic population and comment on one or more indi-
cators of iodine status.
Population groups
The systematic reviews included in this rapid scoping
exercise cover populations of pregnant women and
women of reproductive age through to subjects of age
18, and three reviews also include adults in addition to
children [21, 33, 34]. Only one study looks at the peri-
conceptual period and pregnancy [9], including all
women of reproductive age. Ibrahim and colleagues re-
view only preterm infants of less than 37 weeks gestation
[31]. One review specifies children under 5 years [8],
three focus on school-age children [32, 35, 36], and one
considers minors until age 18 [30]. One systematic re-
view does not look at specific population groups, since
its aim is instead to examine studies investigating iodine
intake in relation to biomarkers of iodine status [33].
Here, no population group is excluded, except patient
populations.
Control groups
Controls used in the included systematic reviews are
placebo [8, 21, 30, 31, 33], no supplementation of iod-
ine [31, 32], absence of iodine between exposure
groups [9] unfortified foods or foods fortified with
only one or two micronutrients [35], low doses of sup-
plements [32, 33], other iodine supplements [21, 30],
historical controls [8] and iodine sufficient siblings
used as a control [8]. Two systematic reviews did not
specify control groups [34, 36].
Outcomes
Table 2 provides a summary of the outcomes defined
within each systematic review. As can be seen from the
table, only half of the included systematic reviews in-
clude pre-defined growth outcomes [9, 21, 30, 34, 35].
Amongst the remaining reviews, three address cognitive
outcomes [8, 32, 36] (a fourth review, discussed below,
cites cognitive development as a primary outcome with
growth as a secondary outcome [9]). One review looks
specifically at premature infant morbidity and mortality
[31]. Lastly, Ristić-Medić et al. [33] investigate bio-
markers of iodine.
Studies including growth-related outcomes Of the five
reviews including growth outcomes, none conducted meta-
analyses. Growth outcomes in these reviews are included as
either primary and secondary outcomes, but generally, out-
comes are not explicitly defined, with authors preferring to
describe outcomes under the umbrellas of “childhood
growth” [9], “physical development” [21, 30] and “childhood
development (including growth)” [34]. That said, one sys-
tematic review states precise measures of growth, namely
“prevalence of stunting, wasting or underweight” in
addition to a more general outcome of “indicators of
growth or body composition” [35]; this study investigated
the effects of multiple micronutrients on the growth, health
and cognition of school children, so inclusion of such terms
is expected. Upon examination of the exact search terms
used in these systematic reviews, two included a search
term for growth (“physical, body growth” [9], and “growth
and development” [34]), one review used “development”
only [21], and one review used no growth or development
terms at all [30]. (The final review of the five described did
not publish their search terms [35].) One review looked
specifically at the effects of iodine supplementation during
pregnancy or the periconceptual period on later child de-
velopment [9], the other four reviews considered postnatal
growth, including school-age children [35], children to age
18 years [30], and all ages including adults [21, 34].
Despite the intentions of these reviews, evidence on ef-
fects of iodine supplementation or fortification on som-
atic growth outcomes was sparse. Best et al. [35] report
on four studies which showed a significant effect on
weight and body mass index (BMI) in school children
receiving fortified foods, however this was achieved with
multiple micronutrient interventions and improved out-
comes could not be attributed to iodine alone. Ange-
meyr and Clar [30], investigating iodine supplementation
in any form on children under 18 years, found one study
where significant differences were found for two mea-
sures of physical stamina, however the other four studies
which reported on growth did not see significant differ-
ences in physical development during the time periods
investigated. Most studies included in this review
assessed the use of iodised oil with only a few looking at
other forms of iodine supplementation. This review thus
offers little evidence on physical development from all
forms of iodine supplementation. Gunnarsdottir and
Dahl [34] in their broad literature review found only
cross-sectional studies reporting on growth. Zhou et al.
[9] consider iodine supplementation in pregnancy, and
discuss at length two older studies (>40 years) conducted
in regions of severe iodine deficiency where growth was
investigated, however, no other trials reporting growth
outcomes were included. Wu et al. [21] do not discuss
any growth outcomes in their results.
Methodological quality
The total AMSTAR scores for the included papers are
shown in Fig. 2. No reviews were rated as “high” meth-
odological quality, a score of 9 or more. Most reviews
were rated as “moderate”, i.e., scoring between 5 and 8
[8, 9, 21, 30–35], and one review achieved a low score (4
or less) [36].
The chart in Fig. 3 details the scoring in each domain.
The most common “problem domains” (domains 4, 5, 7,
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Table 2 Summary of pre-defined outcomes investigated in included systematic reviews
Systematic
review refe
Growth indicators
(weight, height,
stunting, wasting,
strength)
Pregnancy/
birth
outcomes
Iodine
status (UIC,
goitre rate)
Thyroid function
(thyroid hormones
(Tg, TSH), thyroid
volume, hyper-
& hypothyroidism)
Analytical
methods to
assess iodine
status
Cognitive outcomes
(performance,
mental development
score, psychomotor
development)
Academic
performance,
IQ, school
absence
Health related
quality of life,
socioeconomic
effects
Health related
quality of life,
socioeconomic
effects Compliance
with supplement/
fortification,
acceptability, costs
Adverse
events/
morbidity,
mortality
Prevalence of
micronutrient
deficiencies
Taylor et al.,
2014 [32]
✗ ✗ ✗ ✓ ✗ ✓ ✗ ✗ ✗ ✗ ✗
Bougma et al.,
2013 [8]
✗ ✗ ✗ ✗ ✗ ✓ ✗ ✗ ✗ ✗ ✗
Ristić-Medić
et al., 2014
[33]
✗ ✗ ✗ ✓ ✓ ✗ ✗ ✗ ✗ ✗ ✗
Khor & Misra,
2012 [36]
✗ ✗ ✗ ✗ ✗ ✓ ✓ ✗ ✗ ✗ ✗
Best et al.,
2011 [35]
✓ ✗ ✗ ✗ ✗ ✓ ✓ ✗ ✗ ✓ ✓
Gunnarsdottir
& Dahl, 2012
[34]
✓ ✓ ✗ ✓ ✗ ✓ ✗ ✗ ✗ ✗ ✗
Zhou et al.,
2013 [9]
✓ ✗ ✓ ✓ ✗ ✓ ✗ ✗ ✗ ✓ ✗
Ibrahim et al.,
2006 [31]
✗ ✗ ✓ ✓ ✗ ✓ ✗ ✗ ✗ ✓ ✗
Angermeyr &
Clar, 2004 [30]
✓ ✗ ✓ ✓ ✗ ✓ ✗ ✓ ✓ ✓ ✗
Wu et al.,
2002 [21]
✓ ✗ ✓ ✓ ✗ ✓ ✗ ✓ ✓ ✓ ✗
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8, 10; Fig. 3), where methodological quality points were
not gained are discussed below. Only one review in-
cluded explicit statements about publication status as an
inclusion criterion [31]. Ideally systematic reviews should
include both published and unpublished studies or “grey
literature” [37], and authors should state that searches
were conducted regardless of study publication type and
whether studies were excluded based on publication status
or other factors such as language. A list of included and
excluded studies is also not provided in many of the eli-
gible systematic reviews [8, 9, 32, 33, 35, 36]. The
AMSTAR tool also states that methods of assessing scien-
tific quality of studies should be stated a priori, and that
the scientific quality of data should be taken into account
when reaching conclusions and explicitly stated when
making recommendations based upon study results [26].
An assessment of the scientific quality of included studies
is missing in one systematic review [36], and two further
reviews fail to state the methods of assessment a priori
[31, 35]. Of the other systematic reviews, three state the
intent to use Cochrane tools (Cochrane Risk of Bias tool;
Cochrane Handbook) in assessing the scientific quality of
included literature [9, 21, 33], three reviews [21, 30, 32]
also discuss using a modification of previously published
quality criteria recommendations by Jadad [38] and/or
Schultz [39], two reviews describe the use of other tools
[32, 34], and one review does not specify the use of a par-
ticular tool to assess the scientific quality of included lit-
erature, however describes the methodology intended to
be used [8]. Three reviews fail to integrate the scientific
quality of the included studies into the certainty of the re-
view findings and conclusions [34–36]. Lastly, none of the
systematic reviews assessed the likelihood of publication
bias, a known threat to the validity of systematic reviews
[27]. The AMSTAR developers Shea et al. [26, 27] state
that assessments of publication bias should include a
Fig. 2 AMSTAR rating of studies. Note: denominator of 11 for systematic reviews including a meta-analysis; denominator of 10 for narrative
systematic reviews. Red colour indicates meta-analyses; blue indicates narrative systematic reviews
Fig. 3 Breakdown of AMSTAR score per domain
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combination of graphical aids e.g., funnel plots and/or
statistical tests [8, 32, 33].
Discussion
The objective of this rapid scoping review was to iden-
tify the scope, methodological quality and nature of
existing systematic reviews that have investigated the
effects of iodine supplementation or fortification on
prenatal and postnatal growth in children and adoles-
cents. This scoping review has identified gaps in the
evidence base related to this this question and has facil-
itated and informed the development of a protocol for
a new systematic review that will specifically seek to ad-
dress these gaps [40].
We identified ten systematic reviews that investigate
health-related issues associated with iodine intake. As-
pects covered include thyroid function, iodine deficiency
disorders, pregnancy outcomes, cognitive development,
and growth. One review also looks at iodine biomarkers
and the relationship to iodine intake. Most reviews
evaluate iodine supplementation in one or many forms.
Participants are mainly school-age children, though most
reviews also include other population groups, i.e., adults,
pregnant women and preterm infants. Most comparison
groups entail a placebo or no iodine supplementation.
Methodological quality of the included systematic re-
views can be deemed as fair, with nine out of the ten re-
views scoring a “moderate” rating using the AMSTAR
tool. One review was rated as having low methodological
quality [36]. AMSTAR domains where systematic re-
views did not score well were the use of publication sta-
tus as an inclusion criterion, and the evaluation of
publication bias. These points are particularly important,
since publication bias is a well-described threat to sys-
tematic review validity [27], and the inclusion of all eli-
gible studies in systematic reviews and meta-analyses is
required to reduce this risk of bias [37].
Five of the ten systematic reviews included in this
rapid scoping review include growth outcomes within the
scope of their literature examination [9, 21, 30, 34, 35].
Only one narrative systematic review published in 2004,
assesses the effect of improved iodine nutrition on the
physical development of children below the age of 18, via
any form of population-based iodine supplementation or
fortification strategy [30]. However, this review does not
offer comprehensive, up-to-date synthesised evidence on
the effects of iodine nutrition on growth. Furthermore,
prenatal growth outcomes or supplementation during
pregnancy are not included, and the review does not in-
corporate any specific growth outcomes in its search
terms, hence some studies with a focus on growth may
have been missed. Lastly, this review is over ten years old,
and will thus not consider the most recent literature. The
further four reviews which include growth outcomes give
only little discussion on growth, if any, and again, do
not cover all relevant population groups. Two of these
systematic reviews specify populations with low iodine
intake [21, 30], and a further review reports on studies
conducted in regions of severe deficiency [9]. Only one
systematic review included in this scoping review at-
tempts to clarify the dose–response relationship be-
tween iodine status and iodine intake [33], but despite
the inclusion of thyroid function markers, this review
was not focused on health outcomes, and thus could
not clarify to what point iodine deficiency may affect
growth (i.e., at mild deficiency, or just moderately or
severely deficient settings). Overall, these results point
to a lack of synthesised and up-to-date evidence on the
effects of iodine on somatic growth from the prenatal
period up to age 18 years.
Conclusion
This scoping review identifies a gap in the current evi-
dence base on iodine for growth. None of the identified
systematic reviews investigate the effects of all forms of
iodine supplementation/fortification in all of the relevant
population groups (i.e., women of childbearing age, preg-
nant and lactating women and children of all ages) on
all of the relevant growth and growth-related outcomes.
A good quality systematic review of studies investigating
the effects of all forms of iodine supplementation and
fortification in all relevant population groups on prenatal
and postnatal somatic growth is needed to address this
gap, and would provide important evidence on strategies
to prevent stunting. This rapid scoping review has in-
formed and supported the development and publication
of a protocol for a new systematic review [40] that will
examine the effects of all forms of iodine supplementa-
tion and fortification on somatic growth throughout the
life stages of the child. The results of this systematic re-
view have the potential to contribute to and enhance the
evidence base that can inform decisions regarding iodine
supplementation/fortification and child growth.
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